Newamsterdam Pharma CO NV Schedule 13G passive stakes

FMR LLC and Abigail P. Johnson have reported a combined beneficial ownership of 8.8% in NewAmsterdam Pharma Company NV as of June 30, 2026.

Capital World Investors has reported a 10.4% beneficial ownership stake in NewAmsterdam Pharma Company N.V. as of May 29, 2026.

FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, reporting beneficial ownership of 8,765,811 shares, representing 7.6% of NewAmsterdam Pharma Company NV's common stock as of March 31, 2026.

FMR LLC and Abigail P. Johnson have reported a 5.7% beneficial ownership stake in NewAmsterdam Pharma Company NV's common stock as of December 31, 2025.

Capital World Investors has increased its beneficial ownership in NewAmsterdam Pharma Company N.V. to 8.7% of common stock.

Capital World Investors reports a 7.5% passive stake in NewAmsterdam Pharma Company N.V., holding over 8.3 million shares.

RA Capital Management, L.P. and its affiliates have filed an amended Schedule 13G, reaffirming their beneficial ownership of 9.9% of NewAmsterdam Pharma Company N.V.'s Ordinary Shares as of March 31, 2025.

Capital World Investors, a prominent investment adviser, has disclosed a beneficial ownership of 6.2% of the common stock of NewAmsterdam Pharma Company N.V., totaling 6,798,598 shares.

RA Capital Management, along with Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P., have filed an amended Schedule 13G/A, confirming their continued beneficial ownership of 9.9% of NewAmsterdam Pharma Company N.V.'s Ordinary Shares as of December 31, 2024.

Viking Global Investors LP and its affiliated entities have reported a beneficial ownership of 6.5% in NewAmsterdam Pharma Co N.V., totaling 6,978,534 ordinary shares.